Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 31:13:1117160.
doi: 10.3389/fcimb.2023.1117160. eCollection 2023.

A review of penicillin binding protein and group A Streptococcus with reduced-β-lactam susceptibility

Dingle Yu  1 , Danchun Guo  1 , Yuejie Zheng  1 , Yonghong Yang  1   2
Affiliations
Review

A review of penicillin binding protein and group A Streptococcus with reduced-β-lactam susceptibility

Dingle Yu et al. Front Cell Infect Microbiol. .

Abstract

With the widespread use of antibiotics, antimicrobial resistance (AMR) has become a global problem that endangers public health. Despite the global high prevalence of group A Streptococcus (GAS) infections and the global widespread use of β-lactams, β-lactams remain the first-line treatment option for GAS infection. β-hemolytic streptococci maintain a persistent susceptibility to β-lactams, which is an extremely special phenomenon in the genus Streptococci, while the exact current mechanism is not known. In recent years, several studies have found that the gene encoding penicillin binding protein 2X (pbp2x) is associated with GAS with reduced-β-lactam susceptibility. The purpose of this review is to summarize the current published data on GAS penicillin binding proteins and β-lactam susceptibility, to explore the relationship between them, and to be alert to the emergence of GAS with reduced susceptibility to β-lactams.

Keywords: Pbp2x; Penicillin binding protein; Streptococcus pyogenes; antibiotic resistance; group A Streptococcus (GAS); reduced-penicillin susceptibility; β-lactam.

PubMed Disclaimer

Conflict of interest statement

The authors indicated that this study was conducted without any commercial or financial relationships that could be interpreted as potential conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amábile-Cuevas C. F., Hermida-Escobedo C., Vivar R.l. (2001). Comparative in vitro activity of moxifloxacin by e-test against Streptococcus pyogenes . Clin. Infect. Dis. 32 (Suppl 1), S30–S32. doi: 10.1086/319373 - DOI - PubMed
    1. Ambler R. (1980). The structure of beta-lactamases. Trans. R Soc. Lond B Biol. Sci. 289 (1036), 321–331. doi: 10.1098/rstb.1980.0049 - DOI - PubMed
    1. Athey T., Teatero S., Sieswerda L., Gubbay J., Marchand-Austin A., Li A., et al. . (2016). High incidence of invasive group a streptococcus disease caused by strains of uncommon emm types in thunder bay, Ontario, Canada. J. Clin. Microbiol. 54 (1), 83–92. doi: 10.1128/jcm.02201-15 - DOI - PMC - PubMed
    1. Barcus V. A., Ghanekar K., Yeo M., Coffey T. J., Dowson C. G. (1995). Genetics of high level penicillin resistance in clinical isolates of Streptococcus pneumoniae . FEMS Microbiol. Lett. 126 (3), 299–303. doi: 10.1111/j.1574-6968.1995.tb07433.x - DOI - PubMed
    1. Ben Zakour N. L., Davies M. R., You Y., Chen J. H. K., Forde B. M., Stanton-Cook M., et al. . (2015). Transfer of scarlet fever-associated elements into the group a streptococcus M1T1 clone. Sci. Rep. 5 (15877), 1–7. doi: 10.1038/srep15877 - DOI - PMC - PubMed

Publication types

MeSH terms